Full-text resources of PSJD and other databases are now available in the new Library of Science.
Visit https://bibliotekanauki.pl

PL EN


Preferences help
enabled [disable] Abstract
Number of results
2017 | 28 | 108 | 196-201

Article title

Evaluation of anti-manic activity of pregabalin in a mouse model of methylphenidate-induced mania

Content

Title variants

Languages of publication

EN EO

Abstracts

EN
Mania is a psychiatric disorder which may occur alternately with depression as a bipolar disorder, or much less often as an individual disease. It might be accompanied by other disorders, i.e. schizophrenia, dementia or withdrawal syndrome. Only a few effective drugs are used for the treatment of mania. Patients suffering from bipolar disorder are treated with mood-stabilizing drugs, administered during the course of the disease, and drugs that are implemented when mania or depression episodes occur. Some studies report effectiveness of anticonvulsant drugs in the cessation of mania, thus in our study we assessed the effectiveness of pregabalin in a mouse model of mania induced by administration of metylphenidate (5 mg/kg; s.c). Pregabalin was tested in the forced swim test (75 mg/kg, 100 mg/kg; i.p.) and the elevated plus maze test (75 mg/kg; i.p.) to assess its antidepressant-like and anxiolytic-like properties, respectively. In the elevated plus maze in MPH-treated mice pregabalin significantly reduced time spent in open arms (p<0.001 vs. MPH-treated control). In the forced swim test MPH compared to vehicle significantly (p<0.001) reduced duration of immobility. In MPH-treated mice pregabalin partially reversed this effect of MPH. This effect was significant only for the dose of 75 mg/ kg (p<0.05). In the rotarod test neither MPH, nor its combination with pregabalin (75 mg/kg; 100 mg/kg) influenced motor coordination of mice at any speed tested. To conclude our study revealed that pregabalin might reverse manic-like action of MPH related to hyperlocomotion, which may indicate for its possible effectiveness in mania episodes.

Year

Volume

28

Issue

108

Pages

196-201

Physical description

Contributors

author
author
  • Department of Pharmacodynamics, Faculty of Pharmacy, Jagiellonian University, Medyczna 9, PL 30-688 Cracow

References

  • 1. Muneer, A. Chonnam Med. J. 2017, 53, 1-13.
  • 2. Geddes, J.R.; Briess D. BMJ Clin. Evid. 2007, 1014.
  • 3. Cipriani, A.; Saunders, K.; Attenburrow, M.J.; Stefaniak, J.; Panchal, P.; Stockton, S.; Lane, T.A.; Tunbridge, E.M.; Geddes, J.R.; Harrison, P.J. Mol. Psychiatry 2016, 21, 1324–1332.
  • 4. Ashok, A.H.; Marques, T.R.; Jauhar, S.; Nour, M.M.; Goodwin, G.M.; Young, A.H.; Howes, O.D. Mol. Psychiatry. 2017. Doi: 10.1038/Mp.2017.16
  • 5. Gitlin, M. Int. J. Bipolar Disord. 2016, 4, 27.
  • 6. De Fazio, P.; Gaetano, R,; Caroleo, M.; Pavi, M.; De Sarro, G.; Fagiolini, A.; Sequra-Garcia, C. Neuropsychiatr. Dis. Treat. 2017, 13, 755–766.
  • 7. Sahraian, A.; Bigdeli, M.; Ghanizadeh, A.; Akhondzadeh, S. J. Affect. Disord. 2014, 166, 201–205.
  • 8. Solmi, M.; Veronese, N.; Zaninotto, L.; Van Der Loos, M.L.M.; Gao, K.; Schaffer, A.; Reis, C.; Normann, C.; Anghelescu, I.G.; Corrnell, C.U. CNS Spectr. 2016, 21, 403–418.
  • 9. Salat, K.; Gawlik, K.; Witalis, J.; Pawlica- Gosiewska, D.; Filipek, B.; Solnica, B.; Więckowski K.; Malawska B. Naunyn. Schmiedebergs. Arch. Pharmacol. 2013, 386, 493–505.
  • 10. Salat, K.; Cios, A.; Wyska, E.; Salat, R.; Mogilski, S.; Filipek, B.; Wieckowski, K.; Malawska, B. Pharmacol. Biochem. Behav. 2014, 122, 173–181.
  • 11. Toth, C. Ther. Adv. Drug Saf. 2014, 5, 38–56.
  • 12. Salat, R.; Salat, K. J. Pharmacol. Toxicol. Methods 2015, 71, 95–102.
  • 13. Argoff, C. Evid. Based Med. 2017, 22, 70–71.
  • 14. Li, F.; Ma, J.; Kuang, M.; Jiang, X.; Wang, Y.; Lu, B.; Zhao, X.; Sun, L.; Ma, X. J. Orthop. Surg. Res. 2017, 12, 49.
  • 15. Buoli, M.; Caldiroli, A.; Serati, M. Expert Opin. Drug Metab. Toxicol. 2017, 13, 351–359.
  • 16. Barbosa, F.J.; Hesse, B.; Almeida, R.D.B.; Baretta, I.P.; Boerngen-Lacerda, R.; Andreatini, R. Pharmacol. Rep. 2011, 63, 64–70.
  • 17. Tonelli, D.A.G.; Pereira, M.; Siba, I.P.; Martynhak, B.J.; Correia, D.; Casarotto, P.C.; Biojone, C.; Guimaraes, F.S.; Joca, S.L.; Andreatini R. Fundam. Clin. Pharmacol. 2013, 27, 650–655.
  • 18. Souza, L.S.; Silva, E.F.; Santos, W.B.; Asth, L.; Lobão-Soares, B.; Soares-Rachetti, V.P.; Madeiros, I.U.; Gavioli, E.C. Neurosci. Lett. 2016, 629, 143– 148.
  • 19. Van Den Buuse, M.; Garner, B.; Gogos, A.; Kusljic, S. J. Psychiatry 2005, 39, 550–557.
  • 20. Salat, K.; Podkowa, A.; Kowalczyk, P.; Kulig, K.; Dziubina, A.; Filipek, B.; Librowski, T. Pharmacol. Rep. 2015a, 67, 465–472.
  • 21. Porsolt, R.D.; Bertin, A.; Jalfre, M. Arch. Int. Pharmacodyn. Thérapie 1977, 229, 327–336.
  • 22. Salat, K.; Siwek, A.; Starowicz, G.; Librowski, T.; Nowak, G.; Drabik, U.; Gajdosz, R.; Popik, P. Neuropharmacology 2015b, 99, 301–307.
  • 23. Łaczkowski, K.Z.; Salat, K.; Misiura, K.; Podkowa, A.; Malikowska, N. J. Enzyme Inhib. Med. Chem. 2016, 31, 1576-1582.
  • 24. Post, R.M.; Altshuler, L.L.; Leverich, G.S.; Frye, M.A.; Nolen, W.A.; Kupka, R.W.; Suppes, T.; Mcelroy, S.; Keck, P.E.; Denicoff, K.D.; Grunze, H.; Walden, J.; Kitchen, C.M.; Mintz, J. Br. J. Psychiatry 2006, 189, 124–131.
  • 25. Burdick, K.E.; Braga, R.J.; Nnadi, C.U.; Shaya, Y.; Stearns, W.H.; Malhotra, A.K. J. Clin. Psychiatry 2012, 73, 103–112.
  • 26. Kluge, M.; Hegerl, U.; Sander, C.; Dietzel, J.; Mergl, R.; Bitter, I.; Demyttenaere, K.; Gusomao, R.; Gonzalez-Pinto, A.; Perez-Sola, V.; Vieta,nE.; Juckel, G.; Zimmermann, U.S.; Bauer, M.; Sienaert, P.; Quintao, S.; Edel, M.A.; Bolyos, C.; Ayuso-Mateos, J.L.; Lopez-Garcia, P. BMC Psychiatry 2013, 13, 71.
  • 27. Zohar, J.; Matar, M.A.; Ifergane, G.; Kaplan, Z.; Cohen, H. Eur. Neuropsychopharmacol. 2008, 18, 653–666.
  • 28. Lotarski, S.M.; Donevan, S.; El-Kattan, A.; Osgood, S.; Poe, J.; Taylor, C.P.; Offord, J. J. Pharmacol. Exp. Ther. 2011, 338, 615–621.
  • 29. La Porta, C.; Lara-Mayorga, I.M.; Negrete, R.; Maldonado, R. Eur. J. Pain 2016, 20, 1454–1466.
  • 30. Castagné, V.; Porsolt, R.D.; Moser, P. Eur. J. Pharmacol. 2009, 616, 128–133.
  • 31. Hannestad, J.O.; Cosgrove, K.P.; Della Gioia, N.F.; Perkins, E.; Bois, F.; Bhagwagar, Z.; Seibyl, J.P.; Mcclure-Begley, T.D.; Picciotto, M.R.; Esterlis, I. Biol. Psychiatry 2013, 74, 768–776.
  • 32. Chiapponi, C.; Piras, F.; Piras, F.; Caltagirone, C.; Spalletta, G. Front. Psychiatry 2016,7, 61.
  • 33. Brady, R.O.; Mccarthy, J.M.; Prescot, A.P.; Jensen, J.E.; Cooper, A.J.; Cohen, B.M.; Renshaw, P.F.; Ongur, D. Bipolar Disord. 2013, 15, 434–439.
  • 34. Bhagwagar, Z.; Wylezinska, M.; Jezzard, P.; Evans, J.; Ashworth, F.; Sule, A.; Matthews, P.M.; Cowen, P.J. Biol. Psychiatry 2007, 61, 806–812.
  • 35. Patel, R.; Dickenson, A.H. Pharmacol. Res. Perspect. 2016, 4, E00205.
  • 36. Reinares, M.; Rosa, A.R.; Franco, C.; Goikolea, J.M.; Fountoulakis, K.; Siamouli, M.; Gonda, X.; Frangou, S.; Vieta, E. Int. J. Neuropsychopharmacol. 2013, 16, 485–496.
  • 37. Schaffer, L.C.; Schaffer, C.B.; Miller, A.R.; Manley, J.L.; Piekut, J.A.; Nordahl, T.E. J. Affect. Disord. 2013, 147, 407–410.

Document Type

article

Publication order reference

Identifiers

YADDA identifier

bwmeta1.element.psjd-71f10e49-c1c8-4609-b169-a9aea836b475
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.